CEO and Chairman of the Board of Directors
Mr. Grano was named non-executive Chairman on January 1, 2013 and was named CEO and Chairman in May 2014.
He was previously the Chairman and CEO of UBS Financial Services Inc. (formerly UBS PaineWebber). Mr. Grano was instrumental in helping to bring about the merger of PaineWebber with UBS in 2000. Prior to joining PaineWebber he was with Merrill Lynch for 16 years, holding various senior management positions including Director of National Sales. In 1987 he was named the industry’s best retail marketing executive in a survey conducted by Investment Dealers’ Digest. Former Chairman of the Board of Governors of NASD and a member of the NASD’s Executive Committee. Appointed by President George W. Bush in 2002 to serve as the Chairman of the Homeland Security Advisory Council. He served in this capacity until August 2005. Mr. Grano holds honorary Doctor of Laws degrees from Pepperdine University and Babson College as well as an honorary Doctor of Human Letters degree from Queens College. He also oversees Centurion Holdings LLC, a company that advises private and public companies. Mr. Grano also served in the U.S. Special Forces (Green Berets).
Over the past three decades, Mr. Blech has established some of the leading biotechnology companies in the world. These include Celgene Corporation, ICOS Corporation, Nova Pharmaceutical Corporation, Pathogenesis Corporation, and Genetics Systems Corporation.
Collectively, these companies have produced major advances in a broad array of diseases including the diagnosis and treatment of cancer, chlamydia, sexual dysfunction, cystic fibrosis, and AIDS. Celgene Corporation is one of the world’s leading cancer and hematology companies and has a current value in excess of $55 billion. ICOS Corporation discovered the drug Cialis, and was acquired by Eli Lilly and Company for over $2 billion. Nova Pharmaceutical Corporation developed a new treatment for brain cancer, and after merging with Scios Corporation, was purchased for $2 billion by Johnson and Johnson. Pathogeneses Corporation created TOBI for cystic fibrosis, the first inhaled antibiotic approved by the Food and Drug Administration, and was acquired by Chiron Corp for $660 million. Genetics Systems Corporation developed the first inexpensive and accurate test to diagnosis chlamydia, allowing tens of thousands of babies to be born to women who otherwise would have become sterile from pelvic inflammatory disease. Genetics Systems was acquired for approximately 3% of Bristol Myers’s stock. Mr. Blech is currently a major shareholder and board member of ContraFect Corporation, Cerecor, Inc., Edge Therapeutics and Centrexion Corporation, all private companies. Mr. Blech is on the board of directors for The SpendSmart Payments Company, Medgenics Inc., RestorGenex Corporation and root9B Holdings Group, all public companies. Mr. Blech serves as the chair of the nominating committee for SpendSmart, RestorGenex, and root9B Holdings Group, is on the compensation committee for SpendSmart and Medgenics, and is on the nominating committee for Medgenics.
Mr. Carnahan has a long and distinguished background in business and technology consulting, most recently as a Senior Managing Partner for Accenture.
His tenure there was highlighted by responsibilities that included a variety of Fortune 500 companies, primarily in the financial services and technology sectors. In the years from 1981 to 2009, Mr. Carnahan’s management responsibilities included leading the Systems Integration business (responsible for sales support through delivery resulting in approximately $10 billion in revenues), P&L teams and global delivery and client satisfaction. This role extended beyond US national borders to include on-site work with Accenture and client responsibilities in Europe, Asia and the Americas. He is a well-recognized transformational leader for enterprises seeking technology change and new efficiencies in their worldwide operations.
Mr. Morris has worked in positions involving finance, investments, benefits, risk management and human resources for more than 30 years.
Since 2013 he has been the Vice President of Administration at Swisher Hygiene (a NASDAQ and Toronto Stock Exchange, company). From 2011 to 2012 he was a Vice President of Sales Human Resources for Snyder’s-Lance, Inc. (a NASDAQ listed company with revenues over $1.7 billion). Prior to this he held the positions of Vice President-Human Resource Operations and Senior Director-Benefits and Risk Management for Lance, Inc. for 15 years prior to a merger with Snyders. At Lance, Mr. Morris has served as the Chairman of the Risk Management Committee, chaired the Business Continuity Plan Steering Committee, and was a member of the Corporate Mergers & Acquisitions team. Prior to joining Lance, Mr. Morris held various positions with Belk Stores, Collins & Aikman and Laporte plc. He currently serves as a board member for the Second Harvest Food Bank of Metrolina. Mr. Morris also serves on the audit committee for root9B Holdings Group and chairs the compensation committee.
Anthony Sartor since 2009 Dr. Sartor has served as Chairman and CEO of Paulus, Sokolowski, and Sartor (PS&S), a consulting engineering firm based in New Jersey serving New York, New Jersey, Pennsylvania and Puerto Rico.
Prior to PS&S, Dr. Sartor served as Senior VP of National Grid (formerly KeySpan) and from 2003 until 2009 was President of a subsidiary, National Grid Energy Services. Dr. Sartor served as Commissioner over the Port Authority of New York and New Jersey from 1999 to 2014 where he served as Chairman of the WTC Site Redevelopment Committee and of the Committee for Capital Programs. In addition to chairing these committees he also served on the Security, Governance and Ethics, and Labor committees. Dr. Sartor also was appointed by the Governor of New Jersey as Commissioner, from 1992 – 1999, over the New Jersey Sports and Exposition Authority. Dr. Sartor has a Bachelor of Chemical Engineering from Manhattan College as well as a Masters in Engineering and a Doctorate in Philosophy, both from the University of Michigan.
Mr. Siegel is a Certified Public Accountant, inactive, and a principal in the Business Consulting Group of Rothstein Kass, a top accounting and consulting firm.
From 1974 – 1990 he was managing partner and founder of Siegel Rich and Co, P.C., CPA’s which merged into the firm currently known as WeiserMazars, LLP, where he was a senior partner. He later formed a business advisory firm, Siegel Rich Inc. which eventually became a division of Rothstein Kass.
Mr. Sucoff has over 30 years of securities industry experience encompassing supervisory, banking and sales responsibilities.
Mr. Sucoff currently owns and operates Equity Source Partners, LLC an advisory and consulting firm. He has participated in the financing of more than 100 public and private companies, has raised equity capital and played a role in securing financing for biotech companies including Amgen, Centecor, Genzyme, Genentech, Icos, PathoGenesis, Contrafect and Medgenics.
Mr. Sucoff currently serves on the following Boards of Directors: Contrafect Corp. (CFRX), The SpendSmart Payments Company (SSPC) and root9B Holdings (RTNB). In addition, Mr. Sucoff currently serves as a consultant to Multimedia Platforms, Inc. (MMPW).
Mr. Sucoff is the President of New England Law/Boston and has been a member of the Board of Trustees for over 25 years. He is the Chairman of the Endowment Committee. Mr. Sucoff has recently been a member of the Adjunct Faculty of New England Law/Boston where he taught a third year seminar entitled “Perspectives In Law: Lawyers as Entrepreneurs and as Representatives of Entrepreneurs”. Mr. Sucoff received a B.A. from SUNY Binghamton (1974) and a J.D. from New England School of Law (1977) where he was the Managing Editor of the Law Review and graduated Magna Cum Laude. Mr. Sucoff has been a member of the Bar of the State of New York since 1978.
Board Member & President and COO of root9B Holdings; CEO of IPSA International Services, Regulatory Risk
Mr. Wachtler is a 20-year industry veteran that has served in both sales and operational management roles at IPSA and its former parent company.
Mr. Wachtler was named President and CEO in April 2005 and subsequently led and facilitated two capital restructuring initiatives within IPSA, including the management buy-out in 2005. Mr. Wachtler’s vision transitioned IPSA from being an armed protection and investigations service provider to an international investigative and risk advisory firm. His strategic aptitude has also successfully led to IPSA’s global expansion, adding offices in London, Dubai and Hong Kong in recent years. Mr. Wachtler serves on the Board of Directors of the company and also serves on the board of the BritishAmerican British organization. Mr. Wachtler received a B.A. from the University of Arizona.
Board Member & CEO of root9B, Cybersecurity Solutions
Eric Hipkins is an accomplished cyber and intelligence professional with over 25 years of specialty experience in advanced cyber and technical intelligence operations.
A military veteran with extensive experience across the Department of Defense and commercial community, he is the founder and Chief Executive Officer of root9B. Mr. Hipkins has earned more than 12 nationally recognized certifications, including professionalization by the National Security Agency as an Intelligence Analyst and Adjunct Faculty. Mr. Hipkins holds a Master’s Degree and is a graduate of the prestigious Middle Enlisted Cryptologic Career Advancement Program (MECCAP). His professional background spans numerous positions across the commercial, cyber and cryptology community including senior positions within the U.S. Intelligence Community, Special Programs and Special Operations Community.